FDA clears feline amlodipine as BOAS injectable draws attention

The FDA has approved Amodip, an amlodipine besylate chewable tablet, for the control of systemic hypertension in cats, marking the first FDA-approved veterinary amlodipine product and the second FDA-approved feline hypertension treatment overall. The approval, announced April 29, 2026, gives veterinarians a species-specific alternative to the compounded or off-label human amlodipine products that have long been used in practice. In the same week’s clinical research news, Australian researchers and biotech company Snoretox reported early pilot data suggesting that an injectable therapy, Snoretox-1, may improve breathing in brachycephalic dogs with BOAS, while a separate Science study mapped 493 feline tumors across 13 cancer types and found notable genomic overlap with human cancers. (fda.gov)

Why it matters: For veterinary professionals, the amlodipine approval is the most practice-ready development here. FDA approval can improve dosing consistency, palatability, and client confidence for a condition commonly tied to chronic kidney disease and target-organ damage in cats, while reinforcing the need for regular blood pressure and lab monitoring during treatment. The BOAS injectable is much earlier-stage, but it’s notable because surgery remains the standard of care and outcomes can still be incomplete; if larger trials hold up, it could eventually expand options for dogs that are poor surgical candidates or still symptomatic after surgery. The feline cancer genomics work matters more strategically, pointing toward a future in which comparative oncology may inform both veterinary treatment development and translational research. (fda.gov)

What to watch: Watch for Amodip’s clinical uptake in feline practice, larger controlled trials for Snoretox-1, and whether the new feline cancer atlas begins shaping biomarker-driven oncology studies. (rmit.edu.au)